All In Biotech

NDA 050737 · Novartis

Neoral

Cyclosporine · Oral

Last checked: Nov 19, 2026Latest source record: Sep 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Jun 19, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,166

250 Phase 3, 65 recruiting

FAERS reports

71,471

65,437 serious, 13,460 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 19, 1997 Original approval · Type 6 - New Indication (no longer used)
2 products under this application
  • NEORAL · CYCLOSPORINE 25MG · CAPSULE, ORAL · Prescription
  • NEORAL · CYCLOSPORINE 100MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclosporine" as an intervention, any sponsor and status, largest first.

All 1,166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9,115
  • off label use8,353
  • product use in unapproved indication4,122
  • pyrexia3,717
  • pneumonia2,869
  • diarrhoea2,746
  • condition aggravated2,649
  • nausea2,525
  • cytomegalovirus infection2,257
  • fatigue2,098
  • hypertension2,081
  • renal impairment2,032

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,339
20051,287
20061,416
20071,387
20082,313
20092,478
20102,263
20113,028
20122,467
20131,352
20141,556
20151,530
20161,826
20172,279
20182,692
20193,509
20204,673
20214,283
20225,861
20235,833
20247,165
20256,275
20264,647

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Neoral (Cyclosporine, Modified)

2024 spending

$925K

Beneficiaries

264

1,341 claims

Per beneficiary

$3,505

$3.91 per unit

View as table
YearSpending
2020$1,723,632
2021$1,430,503
2022$1,261,029
2023$1,154,941
2024$925,210

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,203 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.